Life SciencesClinical SciencesMicrobiologyMedical MicrobiologyMicrobiome ResearchNeurodegenerationConstipation ManagementGut MicrobiomeGut MicrobiotaMicrobiome DynamicsMicrobiome DysbiosisParkinson DiseaseBristol Stool Form ScaleGut Microbiome AlterationsGut Microbiome DysbiosisGut Microbiota DysbiosisGut Microbiota EffectsOsteopathic Manipulative TreatmentOsteopathic Manual TherapyPilot Study Design
INTRODUCTION: The gut microbiome appears to be predictive of Parkinson's disease (PD) with constipation. Chronic constipation frequently manifests prior to motor symptoms and impairs quality of life. An osteopathic manipulative medicine (OMM) sequence used physical exam assessment and manual treatment of neuromusculoskeletal dysfunctions pertinent to constipation in PD for this prospective ABA-design study, IRB-NYITBHS1065. The effects of 4 weekly treatments on the gut microbiome among men and women over 40 years old with chronic constipation and PD were investigated. Severity of PD was rated with the Movement Disorders Society-Unified PD rating scale (UPDRS) in six subjects with constipation. Also, the Bristol stool scale and questionnaires validated for constipation were administered for diagnosis, symptom severity, and quality of life during a 4-week control-period (A), 4-weekly OMM-treatments (B), and 2-weeks no-intervention (A). Biweekly stool samples were assessed for normalized microbiota abundance. RESULTS: The mean Bristol rating improved from type 2 (± 1) Pre-OMM to 3 (± 1; p = .167; d = 0.677) Post-OMM. Mean constipation severity significantly decreased (p = .010; d = 1.508) Post-OMM. Mean quality of life significantly improved (p = .041; d = 1.072) Post-OMM. The Pre-OMM mean number of families within the phylum Firmicutes decreased by 3 (p = .043; d = 1.177) Post-OMM. There were significant changes in the normalized abundance of phyla Actinobacteria (p = .040; d = 0.845) and Verrucomicrobia (p = .024; d = 0.675) as well as in genus Roseburia (p = .033; d = 1.109), Intestinimonas (p = .035; d = 0.627) and Anaerotruncus (p = .004) Post-OMM. CONCLUSION: The gut microbiome shifted among individuals with constipation and PD after four weekly treatments with the OMM-sequence. Changes in the gut microbiome Post-OMM were associated with UPDRS results and constipation measures. Clinical trials and studies to develop the gut microbiome into a validated biomarker for PD are necessary to understand the impact of OMM in patients with PD and constipation.
26
Margaret M. Hoehn, Melvin D. Yahr · Neurology · 1967 · 12K citations · Full text
Overdependence on degraded gist memory in Alzheimer's disease.
Neuropsychology · 2006 · 4.7K citations
Gut microbiota are related to Parkinson's disease and clinical phenotype
Filip Scheperjans, Velma T. E. Aho, Pedro A. B. Pereira et al. · Movement Disorders · 2014 · 2K citations · Full text